Natural malaria infection develops after injection of sporoing the immunodominant epitope that is the primary target of zoites into the host by an anopheline mosquito during a antisporozoite immunity. Both recombinant (29) and synblood meal. Although the sporozoites rapidly leave the thetic (31) products representing sequences of the imcirculation by invading host liver cells or through generalmunodominant region of the CS protein have been produced ized phagocytosis, a humoral response to the sporozoites as candidate vaccines. does develop (14. 22. 23). The response involves both Falciparum sporozoite vaccine 1 contains as the antigen sporozoite-precipitating and -ncutralizing antibodies which R32tet32. which is a recombinant gene product produced in act both in vivo (15) and in vitro (11) to impair penetration Escherichia coli as a candidate human malaria vaccine (29) . into or development of the vector stage in host hepatocytes R32tet32 is a construct of 32 tandem copies of a CS tetraor both. Under experimental conditions, protective immupeptide repeating sequence, [(Asn-Ala-Asn-Pro)1s-(Asn-Valnity to sporozoite challenge has been demonstrated in roAsp-Pro)2. fused to 32 amino acids derived from an open dents, monkeys, and humans (3. 16-18). although there have reading frame in the Tcr region of the pASI E. coil expresbeen only limited studies with humans. Whether protective sion plasmid. R32tet32 must contain both B-and T-cell antisporozoite immunity occurs under natural conditions of epitopes to be an effective vaccine. In mice, R32tet32 * infection with human malaria is not known. However, based produces high titers of antibody that react specifically with on studies with the erythrocytic stages of malaria, it is CS protein on the surface of live sporozoites (positive ,-generally appreciated that immunity to natural malaria is circumsporozoite precipitin [CSP] reaction) and inhibits slow to develop, poorly protective, and readily lost on sporozoite infection of human hepatoma cells (1, 29) . At leaving an endemic area (13).
present, falciparum sporozoite vaccine 1 is undergoing phase .-Studies using monoclonal antibodies have shown that the I clinical trials in the United States. target antigen of the immune response is a major polypeptide
We report here on the occurrence of antibodies to * covering the sporozoite surface, the circumsporozoite (CS) R32tet32 and their quantitative and temporal characteristics * protein (21. 30). After pioneering work with the simian in plasma from individuals naturally infected with P. parasite Phvomodium knoiwl.i (7). the gene encoding the CS falciparum malaria. Our observations suggest that antiprotein in Pla.smodium .ailciparuin (5) was cloned and seR32tet32 antibodies were not protective against naturally quenced and the amino acid structure was deduced. The CS occurring malaria in Thailand. It further appears that improtein of P. fiilciparum contains a tetrapeptide sequence munosuppression associated with acute infection acted to repeated 41 times, constituting a central core region containprevent development of an optimal immune response. (26) . Malaria antigen for thick smears was prepared from an 24 to 31 years) were from the same area as the patients. They isolate of P. fai/ciparum collected in southeastern Thailand. were essentially healthy and had negative peripheral blood Plasma samples were tested in twofold dilutions from 1:10 to smears for malaria parasites. Two individuals reported a 1:1,280, and positive, negative, and PBS controls were history of malaria infection during the previous 5 years. incorporated in each sample set. The second antibody was Samples were collected on days 0, 4. 11, 18. 25. 28. 32, 39, goat anti-human IgG conjugated to fluorescein (Sigma Chem-53. and 67 in accordance with the mefloquine study protocol.
ical Co., St. Louis. Mo.). A sample was considered positive None of the subjects had taken any antimalarial medications when it was reactive at a dilution of 1:40. for 1 week before entering the study. After the day 0 blood Statistical analysis. The Student t test (two tailed) was used samples were drawn, the patients were treated (a single 750-to determine the significance of differences between means. or 1.500-mg dose of mefloquine) for malaria, and all subse-IFAT data were log transformed to compute the geometric quent samples were posttreatment. There were 10 patients mean reciprocal titer. The log values were converted back that received 1.500 mg of mefloquine (patients 1, 4. 6. 8. 9, and are reported as reciprocal titers. 14. 15. 16, 19, and 20) and 11 patients that received a 750
.," mg-dose (patients 2. 3. 5. 7. 10. 11. 12. 13. 17, 18. and 21) RESULTS ( Table 1) . Mefloquine doses were equally divided among the eight controls. Individuals whose infection recrudesced were
The characteristics of the malaria patients and healthy treated with quinine and tetracycline Heparinized blood controls are shown in Table 1 . There were 21 adult male -.
samples were separated immediately into plasma and erythpatients. all of whom reported one or more previous symprocytes. and the plasma was stored when collected at -20'C tomatic malaria infections (average. 3 to 4 cases). The and latei in the laboratory at -70°C. Patients were kept in arithmetic mean parasite count on admission was 46,866 the hosp tal until aparasitemic. discharged, and monitored 6,415/ixl of blood. All patients were treated with mefloquine for 67 das.
and monitored for 67 days. The average time in the hospital A second group of controls consisted of 86 individuals before discharge was 4 days. Ten individuals were cured of from a nonimalarious area with no history of clinical malaria infection without further complications during the study infection or antimalarial drug use. All individuals were male period. Two patients were cured of P. falciparum but (ages. 18 to 31 years) and essentially healthy. A single blood experienced Plasinodium vivax infection on about day 35. sample was obtained from each of the controls.
There were seven patients with infections that recrudesced Detection of antibodies to R32tet32 by ELISA. Anti-(average, 23 days). one of whom subsequently also develR32tet32 antibodies were detected by an enzyme-linked oped P. vivax infection on day 66. Two patients were immunosorbent assay (ELISA) by using R32tet32 (29) as the considered to have reinfections on days 66 and 67. All capture antigen in microtiter plates (Immulon 2 "'UJ: Dynapatients had positive IFA titers on admission, and all but one tech Laboratories. Inc.. Alexandria. Va.). Stock R32tet32 had maximum ELISA titers greater than the mean control was diluted to a working concentration of 2 p.g/ml of phosvalue. phate-buffered saline (PBS) containing boiled casein (4
The antibody disappearance curves for 10 patients with pgmll. and 50 p.
1 was added to each of the wells in the uncomplicated malaria who were sampled 10 times over 67
4'
even-numbered columns. PBS-boiled casein without antigen days are shown in Fig. 1 . Natural sporozoite infection was was added to "ells in the odd-numbered columns. The plates estimated to have occurred in these patients 10 to 14 days '" ere covered and incubated overnight. The contents of the before presentation at the clinic (on the average, a person ', wells were then aspirated. and the wells were filled with was symptomatic for about 3 days before seeking treatment). blocking buffer (0.5,,' boiled casein. 0.O051/( thimerosal.
It is not known, however, whether any of the patients were 0.001" phenol red) containing 1% Tween 20 (TW) and held parasitemic but asymptomatic before their clinical episode. for 1 h. The plasma to be tested was diluted 1:100 in blocking Among the 10 uncomplicated cases, the range in maximum butfer containing 0.025', TW. and 50 0.l was added to each of antibody levels to R32tet32 was considerable (0.045 to 2.000 three adjacent even-and odd-numbered-column wells and AU). In the 10 patients with uncomplicated malaria, the incubated for 2 h. The peripheral wells were not used. The maximum antibody response was recorded on day 0 for 6 contents of the wells were then aspirated and washed twice patients and on day 4 for 3 patients. One patient did not have with PBS containing 0.05',r TW. and 50 p.
1 of rabbit antia detectable antibody response. A steep decline in antibody * human immunoglobulin G (fgG) (H-L chains)-peroxidase level was apparent in most patients, with an average halfconjugate (Miles-Yeda Ltd.. Naperville. Ill.) diluted 1:2.00X) maximum absorbance occurring at 27 days. By day 67. the in blocking buffer containing 0.025 ' TW was added to each mean absorbance for all 10 patients was 0.158 AU, which well. After a 1-h incubation, the contents of the wells were was fivefold less than the mean maximum absorbance of 0.81 aspirated. The wells were washed three times with PBS-TW.
AU. 1(" -V1 of peroxidase substrate (Kirkegaard & Perry LaboraThe anti-R32tet32 ELISA curves for 11 patients in whom tories. Gaithersburg. Md.) was added per well. and the A 414 outcomes were complicated (seven recrudescences. two * (reported as absorbance units [AUI) was recorded after I h. reinfections with P. faihiparutm. and three P. viax infecAll incubations were at ioom temperature. The mean negations) are shown in Fig. 2 (see also Table 1 ). Overall. the tive control value (three wells without R32tet32) was subranges of antibody levels and shapes of the curves were tracted from the absorbance values for wells containing similar to those in Fig. 1 . The mean half-maximum absorR32tet32. and a mean value was calculated. Standard bance for this group was at 25 days. Recrudescence of " Antiporozoite antibodies to the R32tet32 antigen as measured by ELISA: maximum and minimum A 414 were measured, and the day the value was recorded is indicated Anti-IE-stage antibodies to P. jah iparum, as measured by IFAT: the day the value was recorded is indicated. * Values for all patients and controls are arithmetic means ± standard errors of the means, except for IFAT titers, which are expressed as geometric means.
rwo individuals reported malaria infection in the previous 5 years. but none reported infection in the previous year, infection or infection with P. vivax appeared not to influence next 36 days, the titer decreased slightly but appeared to the levels of anti-R32tet32 antibodies. In one patient (no. 14, level off. The calculated half-maximum titer. 330, for the Fig. 2 ), parasites were detected on day 67 and there was a anti-IE-stage antibodies occurred on day 34. All individuals sharp rise in antibody level that began after day 53. indicatexcept one had reactive IFAT titers (-40) on day 0, suggesting reinfection with P. fanlciparum. Another patient (no. 19) ing previous clinical infection(s). did not show a change in antibody titer, although parasites were observed on day 66. DISCUSSION The anti-R32tet32 ELISA curves for all 21 patients and the * 8 controls are shown in Fig. 3 . For the patient group, the Antibodies which reacted with the R32tet32 antigen were mean maximum antibody level occurred on day 4 (k, 0.928 clearly present in plasma from individuals naturally infected AU: 95c/ confidence interval [CII, 0.637 to 1,220), with the with P. .falciparum. These studies provide a longitudinal half-maximum absorbance occurring on day 27. The eight profile (67 days) of anti-R32tet32 antibody levels in patients -controls had a mean maximum absorbance over the 67-day treated for symptomatic infection and monitored by sequenperiod of 0.039 AU (9514 CI, -0.015 to 0.093). For compartial sampling. A previous study with randomly collected sera ison, a group of 86 individuals, residing in a malaria-free from The Gambia used an immunoradiometric assay to * region, with no history of clinical malaria infection had a demonstrate that antisporozoite antibodies were reactive mean anti-R32tet32 ELISA titer of 0.040 AU (95% C1. 0.027 with a synthetic dodecapeptide, (NANP)j, which also conto 0.052).
tained the immunodominant epitope of the CS protein (31). The geometric mean levels of IE-stage antibodies for the This same study showed that results from the radiometric group of 21 P. ailciparunm-infected patients are shown in Fig. assay correlated well with an IFAT and that preincubation of .. "
4. The maximum geometric mean titer for the eight controls sera with (NANP) 3 abolished the IFAT reaction to sporoover the 67-day period was 3 (95%4 Cl. 0.6 to 11). The IFAT zoites. * titer for the malaria-infected group peaked on day II (geoAntisporozoite antibodies were first demonstrated in natmetric mean, 661; 95(/ CI, 495 to 884), although there was no ural falciparum infections in 1979 (14) by an IFAT with statistical difference between the titers on days 4 and 11, and glutaraldehyde-fixed sporozoites, the CSP test also was then decreased over the next 21 days. The decrease in the used. Since then other groups (22, 23) hav. used the IFAT IFAT titer %as significant (P < 0.005) by day 28. Over the and CSP test to assess the prevalence of antisporozoite (3, 16) . ..
1.2
Based on grouped data, the results of the study showed a maximum anti-R32tet32 antibody response on day 4 after W' 1.0-presentation for treatment. Only 3 of 20 patients with anti-
4
R32tet32 titers had maximum levels on day 0. On the average, an individual would have received an infective ,0.8 mosquito bite, hence sporozoite exposure, about 10 to 14 4 days before arrival at the clinic. Thus, most patients were experiencing a rising anti-R32tet32 titer at the time a blood 0o6-stage infection developed that was sufficient to cause symptoms. After day 4, there was a relatively steep decline in anti-R32tet32 antibody levels. The calculated half-maximum 0.4€ absorbance for the group was at 27 days. A priori, there is no reason to expect such consistent behavior in antibody re-02 sponse among this number of individuals. In theory, the magnitude and duration of the anti-R32tet32 (sporozoite) 0.0' response depends on multiple parameters: prior and subse- . So it is possible that ate-to-high parasitemias. the suppression involves lymphomefloquine treatment could result in toxicity to T and B cyte responses to heterologous antigens (9) and the humoral lymphocytes, thereby shutting down antibody synthesis. response to various immunizations (28) . A defect in T-helper However. the drug effect would be predicted to be nonspelymphocyte function could disrupt specific B-cell activation cific and, therefore, should produce a generalized suppresand hence disrupt antibody synthesis. In Plasmodium sion of the immune response. Other antimalarial agents, berghei-infected mice the presence of an IE-stage infection such as chloroquine and quinine, have also been shown to was noted to suppress the antibody response to injected suppress lymphocyte responses in vitro. However, both of these antimalarial agents had no effect on the immune response of mice in vivo (25). In fact, immunization of 1.4-rodents with live sporozoites was found to produce good protective responses to subsequent challenge when IE-stage infection was prevented by concomitant administration of "V 1.2 chloroquine (19). Clinical infection was observed to suppress 4 the response in Nigerian children to a meningococcal polysaccharide vaccine (8). However, when children were placed %."
Loon chloroquine -hemoprophylaxis, the response was enhanced (8).
In the lymphocyte study (9) showing malaria antigen-_0.
specific immunosuppression. the responses to streptococcal '.-.8, .
(streptokinase-streptodornase) and tubercular (purified protein derivatie) antigens were not suppressed at low-toS0moderate parasitemius. The individuals in that study were treated with quinine (an aminoquinoline like mefloquine) and "4-tetracycline. Antibody lexels (IFAI ) to the IE stage of P. fah'iparum " ".showed a profile that was similar to that observed for o2-anti-R32tet32. ['he anti-It --tage antibodies appeared to peak on day 11, and the fallotlii he geometric mean titer was less antibody response is consistent with immunosuppression
